GLP-1 receptor agonist — approved, prescription-only.

Also known as: Ozempic, Wegovy, Rybelsus

Dual GIP/GLP-1 receptor agonist — approved, prescription-only.

Also known as: Mounjaro, Zepbound

Triple agonist (GIP/GLP-1/glucagon) — in clinical testing, NOT approved.

Also known as: LY3437943

Synthetic peptide — predominantly animal data, NOT approved for humans.

Also known as: Body Protection Compound 157, PL 14736 (verwandt)

Actin-binding peptide — research substance, NOT approved.

Also known as: TB-500, Thymosin Beta-4, Tβ4

Copper-binding tripeptide — established in topical cosmetics.

Also known as: Kupfer-Tripeptid-1, Copper Peptide, Glycyl-L-Histidyl-L-Lysin:Cu

Growth hormone secretagogues — research peptides, not approved for humans.

Also known as: Modified GRF (1-29), GHRH-Analogon + GHRP, Ipamorelin

HGH fragment — clinically investigated, but not approved as a weight-loss medication.

Also known as: HGH-Fragment 176-191, Anti-Obesity Drug 9604

GHRH analogue — approved prescription-only in the USA (HIV lipodystrophy).

Also known as: Egrifta

Neuropeptide — registered as a medicine in Russia, not approved in the EU/USA.

Also known as: ACTH(4-7)-Analogon, Heptapeptid

Anxiolytic neuropeptide (tuftsin analogue) — registered in Russia, not approved in the EU/USA.

Also known as: TP-7, Tuftsin-Analogon

Cosmetic peptide — topical in anti-aging formulations.

Also known as: Acetyl Hexapeptide-3, Acetyl Hexapeptide-8

Cosmetic matrikines — topical to stimulate collagen formation.

Also known as: Palmitoyl Pentapeptide-4, Palmitoyl Tripeptide-1, Palmitoyl Tetrapeptide-7

Synthetic tetrapeptide — research substance for aging, not approved.

Also known as: Epithalon, AEDG, Ala-Glu-Asp-Gly

Immunomodulating peptide — approved as Zadaxin in several countries, not FDA-approved.

Also known as: Tα1, Zadaxin, Thymalfasin

GHRH analogue — was approved as Geref, today no approved finished medicinal product.

Also known as: Geref, GHRH (1-29), Sermorelin-Acetat

Synthetic ghrelin mimetic — traded as a research substance, banned in sport.

Also known as: Pralmorelin, KP-102, Growth Hormone Releasing Peptide-2

The first GH-releasing peptide — a strong appetite trigger, not approved.

Also known as: Growth Hormone Releasing Peptide-6, SKF-110679

The strongest GH releaser of the GHRP group — with desensitization and cardiac research.

Also known as: Examorelin, HEX

The real recombinant growth hormone — approved, prescription-only, banned in sport.

Also known as: rhGH, Genotropin, Norditropin

Melanocortin agonist for sexual desire — approved in the USA as Vyleesi.

Also known as: Bremelanotid, Vyleesi, PT-141

A tanning peptide without approval — with documented melanoma and priapism cases.

Also known as: MT-II, MT-2

Approved as an implant (Scenesse) — but only for the rare light disease EPP, not for tanning.

Also known as: Afamelanotid, Scenesse, MT-1

A mitochondrially encoded peptide — an "exercise mimetic" of research, not approved.

Also known as: MOTSc, Mitochondrial ORF of the 12S rRNA type-c

A cardiolipin-stabilizing mitochondrial peptide — approved in the USA for Barth syndrome in 2025.

Also known as: Elamipretid, Bendavia, MTP-131

Not a peptide but an NNMT inhibitor — fat-metabolism research without human data.

Also known as: 5-Amino-1-Methylquinolinium, NNMT-Inhibitor

An anti-inflammatory tripeptide from the α-MSH terminus — gut and research focus, not approved.

Also known as: Lysin-Prolin-Valin, α-MSH(11-13)

A neuropeptide with contradictory sleep evidence — not approved.

Also known as: Delta Sleep-Inducing Peptide, Delta-Schlaf-induzierendes Peptid

Endogenous antimicrobial peptide of the innate immune defense — experimental, not approved as a medicine.

Also known as: Cathelicidin LL-37, hCAP18/LL-37, CAMP

Endogenous myostatin and activin inhibitor from muscle research — experimental, not approved as a medicine

Also known as: Follistatin, FST, FS

Mitochondria-derived 24-amino-acid peptide from neuro- and longevity research — experimental, not approved.

Also known as: HN, Humanin (HN), HNG (S14G-Humanin, Analogon)

Endogenous 28-amino-acid neuropeptide with immunomodulatory action — as the drug aviptadil it is in clinical testing, not broadly approved

Also known as: VIP, Vasoaktives Intestinales Peptid, Vasoaktives intestinales Polypeptid

Reproductive neuropeptide of the GnRH axis — subject of clinical research, not approved.

Also known as: Kisspeptin-54, Kisspeptin-10, KP-54

Approved, prescription-only GLP-1 receptor agonist for type 2 diabetes and obesity – a predecessor of semaglutide and not a substance for self-administration.

Also known as: Victoza, Saxenda, Liraglutide

Long-acting GLP-1 receptor agonist (Fc fusion protein), once weekly – an approved prescription diabetes medication.

Also known as: Trulicity, LY2189265, Dulaglutide

Synthetic exendin-4: the first approved GLP-1 receptor agonist — originally derived from the saliva of the Gila monster.

Also known as: Byetta, Bydureon, Bydureon BCise

Long-acting amylin analogue in clinical investigation for weight regulation – not approved.

Also known as: Cagrilintide, AM833, NNC0174-0833

Experimental dual GLP-1/glucagon receptor agonist – in clinical trials for obesity and MASH, not approved anywhere.

Also known as: BI 456906, Survodutide (INN)

Dual GLP-1/glucagon receptor agonist (oxyntomodulin analog), approved in China, under investigation elsewhere

Also known as: Mazdutide, IBI362, LY3305677

Approved MC4R agonist for narrowly defined rare forms of obesity — genetic forms plus (in the US since 03/2026) the acquired hypothalamic form; not a general weight-loss drug.

Also known as: Imcivree, RM-493, BIM-22493

Heavily hyped "next-gen BPC-157" – almost no human data, no PDA-specific studies, not approved as a medicine.

Also known as: PDA, Pentadecapeptid-Arginat, BPC-157 Arginat

Non-erythropoietic EPO derivative being investigated in early clinical trials as an agonist of the "innate repair receptor" against neuropathic symptoms.

Also known as: Cibinetide, ARA290, ARA 290

Selective growth hormone secretagogue — research peptide, never approved as a medicine.

Also known as: NNC 26-0161, Ipamorelin-Pentapeptid, selektives GH-Sekretagogum (GHRP)

Makes it clear: IGF-1 LR3 is a laboratory/research reagent, not a medicine approved for humans – with serious, genuinely documented risks (including hypoglycaemia) and banned in sport.

Also known as: Long R3 IGF-1, LongR3 IGF-I, Long R3 IGF-I

Peptide mixture derived from porcine brain with neurotrophic marketing claims – evidence inconsistent according to Cochrane.

Also known as: FPF-1070, FPF 1070, Cerebrolysinum

A peptide fraction derived from the thymus gland, studied primarily by Russian research groups (Khavinson) as an immunomodulator and "geroprotector" – with only limited independent confirmation.

Also known as: Thymalin, Thymus-Peptidfraktion, Thymus-Peptidpräparat

A controversially debated growth factor from anti-aging research – made famous by "young blood" studies whose findings were later scientifically contested. Not an approved agent.

Also known as: Growth Differentiation Factor 11, GDF11, BMP-11

Nine-residue posterior-pituitary hormone: an approved obstetric medicine — separately marketed as an intranasal "cuddle hormone" (mixed evidence).

Also known as: Oxt, OXT, Syntocinon

Synthetic GnRH/LHRH – the hypothalamic releasing hormone that prompts the pituitary to secrete LH and FSH.

Also known as: GnRH, LHRH, Gonadotropin-Releasing-Hormon

Experimenteller GLP-1- und Amylin-Rezeptoragonist in einem einzigen Molekül - Phase 3, nicht zugelassen.

Also known as: NN9487, NNC0487-0111, Amycretin (Novo Nordisk)

Erster oraler PCSK9-Hemmer als Tablette – makrozyklisches Peptid zur LDL-Cholesterin-Senkung.

Also known as: Lipfendra, MK-0616, Enlicitide decanoate

Monatlicher Studienwirkstoff von Amgen gegen Adipositas — GLP-1-Agonismus plus GIP-Rezeptor-Blockade, noch ohne Zulassung.

Also known as: MariTide, AMG 133, Maridebart cafraglutide

Der prominenteste Tirzepatid-Herausforderer außerhalb von Lilly und Novo – dual auf GLP-1 und GIP, in Phase 3, aber noch nirgends zugelassen.

Also known as: VK2735, VK-2735

Langwirksames Parathormon-Prodrug – erste zugelassene Ersatztherapie beim chronischen Hypoparathyreoidismus des Erwachsenen.

Also known as: Yorvipath, TransCon PTH, Palopegteriparatide

Untersuchter, balancierter Glukagon-/GLP-1-Doppelagonist mit Schwerpunkt Leber (MASH) – nicht zugelassen.

Also known as: Pemvidutide, ALT-801, ALT801

Fixkombination aus zwei injizierbaren Peptiden — dem Amylin-Analogon Cagrilintid und dem GLP-1-Agonisten Semaglutid — zur Gewichtsreduktion; Phase 3 abgeschlossen, Zulassungsantrag eingereicht, noch nicht zugelassen.

Also known as: Cagrilintid/Semaglutid-Fixkombination, Cagrilintide/Semaglutide, CagriSema (Novo Nordisk)

Langwirksames GLP-2-Analog in der Prüfphase – untersucht beim Kurzdarmsyndrom, mit nur wöchentlicher Gabe, aber (Stand August 2026) nirgends zugelassen.

Also known as: FE 203799, Apraglutide, GlyPharma GLP-2-Analog

Langwirksamer Amylin-Analog in Phase 3 – zweistelliger Gewichtsverlust bei nahezu placeboähnlicher Magen-Darm-Verträglichkeit (nicht zugelassen).

Also known as: Petrelintide, ZP8396, Petrelintid (Roche/Zealand)